Ultimovacs ASA: Mandatory notification of trade by primary insider
December 19, 2023 10:51 ET
|
Ultimovacs ASA
Oslo, 19 December 2023, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at an average price of...
Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint
December 18, 2023 01:00 ET
|
Ultimovacs ASA
Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpointData included observations of immune activation with...
Ultimovacs Announces Resignation of Aitana Peire from Board of Directors
November 28, 2023 01:00 ET
|
Ultimovacs ASA
Oslo, November 28, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announces that Aitana Peire, Ph.D., has...
Ultimovacs ASA: Mandatory notification of trade by primary insider
November 21, 2023 11:00 ET
|
Ultimovacs ASA
Oslo, 21 November 2023, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 500 shares in the company at an average price of NOK...
Ultimovacs ASA: New share capital registered
November 13, 2023 04:46 ET
|
Ultimovacs ASA
Oslo, 13 November 2023, Ultimovacs ASA (the "Company") refers to the announcement published on 9 November 2023 regarding the issuance of new shares in connection with the Company's employee incentive...
Ultimovacs ASA: Share capital increase related to exercise of options
November 09, 2023 11:00 ET
|
Ultimovacs ASA
Oslo, 09 November 2023, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital by NOK 960 through the issuance of 9,600 new shares, each with a...
Ultimovacs ASA: Mandatory notification of trade by primary insider
November 08, 2023 05:18 ET
|
Ultimovacs ASA
Oslo, 8 November 2023, Jónas Einarsson, a primary insider and chair of the board of the Company, has today bought 5,300 shares in the company at an average price of NOK 93.95 per share. Following this...
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update
November 08, 2023 01:00 ET
|
Ultimovacs ASA
Oslo, November 8, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its third quarter 2023 results today. ...
Ultimovacs ASA: Invitation to third quarter 2023 results webcast presentation
November 02, 2023 03:00 ET
|
Ultimovacs ASA
Oslo, November 2, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its third...
Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma
November 02, 2023 02:00 ET
|
Ultimovacs ASA
The supplementary study to INITIUM is designed to provide in-depth data on the biological activity and mode of action of the vaccine-induced T cells, to support the next stages of...